With this agreement, Cyagen obtains rights to distribute genOway’s preclinical humanized immune checkpoint and immunodeficient BRGSF mouse models in the Asia-Pacific region.
Lyon, France, December 1, 2020 – Cyagen and genOway, two innovative companies and leaders in the creation of genetically engineered rodent models, announced a partnership to commercialize high-standard preclinical humanized immune checkpoint and immunodeficient BRGSF mouse models to nonprofit and for-profit organizations in the Asia-Pacific region from 2020 on.
“Cyagen and genOway are among the leaders in the field of genetically engineered models. This alliance will allow our customers in the Asia-Pacific region to access the more scientifically advanced immunodeficient and humanized immune checkpoint mouse models,” Mr. Lanqing Han (Lance), Chairman of Cyagen, said. “Importantly, these models have been co-validated by a consortium of leading immuno-oncology companies (e.g., AbbVie, AstraZeneca, BMS, Pfizer, and Roche), and some of them have been already published in prestigious scientific journals and provided data for IND.”
“We are very excited by this strategic partnership with Cyagen,” said Alexandre Fraichard, founder and General Manager of genOway. “Excellency in science and customer focus are the core values of both companies. This partnership will enable genOway and Cyagen to serve their customers better, by offering them the most advanced and comprehensive portfolio of preclinical mouse models with the necessary intellectual property rights, and help accelerate their research in immuno-oncology and immune-therapy.”
This agreement enables Cyagen to produce, sell and distribute preclinical humanized immune checkpoint and immunodeficient BRGSF mouse models developed by genOway in most of the APAC countries.
Cyagen is an 800-employee company headquartered in Santa Clara, California, with additional locations in Japan and China. As one of the leading providers of genetically engineered mouse and rat models, Cyagen is renowned for its quality, money-back guarantee, and cost-effective prices. Cyagen provides researchers around the world with transgenic, knockout, knock-in, CRISPR, and ES-cell based models and also offers a comprehensive series of stem cell products for research use, including cell lines, media and differentiation kits. From vector and strategy design to animal model creation, cryopreservation and breeding, Cyagen offers complete outsourcing for all animal model needs. Cyagen has served thousands of top laboratories and pharmaceutical companies worldwide over the past 15 years. Its products and services have been cited in over 4,300 publications in high-impact academic journals.
Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway is an international team that employs passionate and dedicated people from 18 nationalities. Its clients include 380 academic institutions and 170 life sciences companies, with 17 of the top 20 pharma. genOway strives to become the preferred partner of all scientists seeking innovative and reliable research tools.
China – www.cyagen.com; Tel: 400-680-8038; Email: email@example.com
APAC region – apac.cyagen.com
South Korea – korea.cyagen.com; Tel: 86 20-31601779; Email: firstname.lastname@example.org
Japan – www.cyagen.jp – Tel: 03-6304-1096; Email: email@example.com
North America and Europe – www.cyagen.com; Tel: +1-800-921-8930 (8-6pm PST) or +1-408-969-0306 (int'l); Email: firstname.lastname@example.org
Tel: +33 (0)4 37 65 41 00; Email: email@example.com